Quick Answer
Rein Therapeutics, Inc. reported Operating Income Loss of -$50.63 million for the year ending 2025.
- Rein Therapeutics, Inc. showed an increase of +22.2% in Operating Income Loss from 2024 to 2025.
- This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$3.94 million | Q2 2016: -$5.55 million | Q3 2016: -$4.23 million | Q4 2016: -$4.45 million | Q1 2017: -$4.59 million | Q2 2017: -$4.95 million | Q3 2017: -$6.43 million | Q4 2017: -$7.04 million | Q1 2018: -$7.76 million | Q2 2018: -$9.66 million | Q3 2018: -$7.50 million | Q4 2018: -$6.98 million | Q1 2019: -$7.31 million | Q2 2019: -$7.38 million | Q3 2019: -$7.92 million | Q4 2019: -$7.35 million | Q1 2020: -$6.88 million | Q2 2020: -$4.40 million | Q3 2020: -$5.03 million | Q4 2020: -$4.19 million | Q1 2021: -$6.99 million | Q2 2021: -$6.01 million | Q3 2021: -$6.79 million | Q1 2022: -$8.42 million | Q2 2022: -$8.04 million | Q3 2022: -$6.48 million | Q1 2023: -$5.01 million | Q2 2023: -$1.99 million | Q3 2023: -$1.98 million | Q1 2024: -$7.21 million | Q2 2024: -$9.04 million | Q3 2024: -$6.07 million | Q1 2025: -$5.61 million | Q2 2025: -$6.87 million | Q3 2025: -$5.49 million.
- Over the full 11 years of available data (2015 to 2025), Rein Therapeutics, Inc.'s Operating Income Loss has declined by 292.8%.
- Historical annual values: Fiscal year 2025: -$50.63 million | Fiscal year 2024: -$65.11 million | Fiscal year 2023: -$16.28 million | Fiscal year 2022: -$27.65 million | Fiscal year 2021: -$26.61 million | Fiscal year 2020: -$20.50 million | Fiscal year 2019: -$29.96 million | Fiscal year 2018: -$31.90 million | Fiscal year 2017: -$23.01 million | Fiscal year 2016: -$18.17 million | Fiscal year 2015: -$12.89 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: